South Korean company acquires AMPAC Fine Chemicals

| By | API, Drug Manufacturing, Innovative Medicines
0
235

SK Holdings, the parent company of South Korea’s third-largest conglomerate SK Group, announced that it has acquired a 100 percent stake in AMPAC Fine Chemicals, a US-based contract manufacturer of active pharmaceutical ingredients.

Established in the 1990s, AMPAC Fine Chemicals (AFC) is a leading global supplier of high value-added APIs and intermediates in medical indications such as cancer, CNS, cardiovascular and anti-viral, having grown more than 15% a year over the past several years.

AFC is strategically located with facilities on the west, east and south coasts of the United States, providing services to a large number of pharma and biotech companies throughout the entire life cycle of their products. AFC capabilities include process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients and registered intermediates for pharmaceutical and biotechnology customers. Its specially engineered facilities and experienced staff allow AFC to safely produce highly energetic compounds at commercial scale. In addition, AFC’s other technology platforms include production of highly potent compounds, continuous processes and industrial-scale chromatographic separation using simulated moving bed chromatography and Analytical Services to the Pharmaceutical Industry.

SK Biotek, a wholly-owned subsidiary of SK Holdings, has built a strong relationship with major global pharmaceutical companies since its inception in 1998 as an API manufacturer. Its portfolio of technologies includes the world’s first low-temperature continuous flow technology, which is considered best-in-class. The combination of SK Biotek’s presence in Europe and Asia and AFC’s robust presence in the US will create a powerful platform to become a global top-tier CDMO in the next 5 years.

SOURCE: prnewswire
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.